Herbalife Reports Second Quarter 2024 Results, Adjusted EBITDA¹ Exceeds Guidance; Raised Full-Year Adjusted EBITDA¹ Guidance
Herbalife (NYSE: HLF) reported Q2 2024 financial results, with net sales of $1.3 billion, down 2.5% year-over-year due to FX headwinds. However, the company achieved 0.2% growth on a constant currency basis. Highlights include:
- Adjusted EBITDA of $180.0 million, exceeding guidance
- Adjusted diluted EPS of $0.54
- Net income of $4.7 million; adjusted net income of $54.8 million
- Gross profit margin improved to 77.9%
- New distributor recruitment increased 12% year-over-year
The company raised its full-year 2024 adjusted EBITDA guidance while reducing net sales guidance. Herbalife also completed a $1.6 billion debt refinancing and sold its Torrance office building for approximately $38 million.
Herbalife (NYSE: HLF) ha pubblicato i risultati finanziari del secondo trimestre 2024, riportando vendite nette di 1,3 miliardi di dollari, con un calo del 2,5% rispetto all'anno precedente a causa delle difficoltà legate ai cambi. Tuttavia, l'azienda ha registrato una crescita dello 0,2% su base di valuta costante. Tra i punti salienti ci sono:
- EBITDA rettificato di 180,0 milioni di dollari, superiore alle previsioni
- EPS diluito rettificato di 0,54 dollari
- Reddito netto di 4,7 milioni di dollari; reddito netto rettificato di 54,8 milioni di dollari
- Margine di profitto lordo migliorato al 77,9%
- Reclutamento di nuovi distributori aumentato del 12% rispetto all'anno precedente
L'azienda ha aumentato le previsioni per l'EBITDA rettificato dell'intero anno 2024, riducendo però quelle sulle vendite nette. Herbalife ha anche completato un rifinanziamento del debito da 1,6 miliardi di dollari e venduto il suo edificio per uffici di Torrance per circa 38 milioni di dollari.
Herbalife (NYSE: HLF) reportó los resultados financieros del segundo trimestre de 2024, con ventas netas de 1.3 mil millones de dólares, que representan una disminución del 2.5% en comparación con el año anterior debido a las dificultades cambiarias. Sin embargo, la compañía logró un crecimiento del 0.2% en términos de moneda constante. Los aspectos destacados incluyen:
- EBITDA ajustado de 180.0 millones de dólares, superando las expectativas
- EPS diluido ajustado de 0.54 dólares
- Ingreso neto de 4.7 millones de dólares; ingreso neto ajustado de 54.8 millones de dólares
- El margen de beneficio bruto mejoró al 77.9%
- Aumento del 12% en el reclutamiento de nuevos distribuidores en comparación con el año anterior
La empresa incrementó su guía de EBITDA ajustado para todo el año 2024 mientras disminuyó la guía de ventas netas. Herbalife también completó un refinanciamiento de deuda de 1.6 mil millones de dólares y vendió su edificio de oficinas en Torrance por aproximadamente 38 millones de dólares.
허벌라이프 (NYSE: HLF)는 2024년 2분기 재무 결과를 발표하며 순매출 13억 달러를 기록했으며, 이는 환율 영향을 고려할 때 지난해 대비 2.5% 감소한 수치입니다. 그러나 회사는 지속 환율 기준으로 0.2% 성장을 달성했습니다. 주요 하이라이트는 다음과 같습니다:
- 조정된 EBITDA는 1억 8천만 달러로 예상을 초과했습니다
- 조정된 희석 주당순이익(EPS)은 0.54 달러
- 순이익 470만 달러; 조정된 순이익은 5,480만 달러
- 총 이익률은 77.9%로 개선
- 새로운 유통업체 모집이 지난해 대비 12% 증가
회사는 2024년 전체 조정된 EBITDA 가이드를 상향 조정했지만 순매출 가이드는 하향 조정했습니다. 허벌라이프는 또한 16억 달러 규모의 부채 재융자를 완료하고, 토랜스에 있는 사무용 건물을 약 3,800만 달러에 매각했습니다.
Herbalife (NYSE: HLF) a annoncé ses résultats financiers pour le deuxième trimestre de 2024, avec des ventes nettes de 1,3 milliard de dollars, soit une baisse de 2,5 % par rapport à l'année précédente en raison de la pression des taux de change. Cependant, l'entreprise a atteint une croissance de 0,2 % sur une base de monnaie constante. Les points forts incluent :
- EBITDA ajusté de 180,0 millions de dollars, dépassant les prévisions
- BPA dilué ajusté de 0,54 dollar
- Revenu net de 4,7 millions de dollars ; revenu net ajusté de 54,8 millions de dollars
- La marge brute a augmenté à 77,9 %
- Recrutement de nouveaux distributeurs en hausse de 12 % par rapport à l'année précédente
L'entreprise a relevé ses prévisions d'EBITDA ajusté pour l'ensemble de l'année 2024, tout en abaissant ses prévisions de ventes nettes. Herbalife a également achevé un refinancement de la dette de 1,6 milliard de dollars et a vendu son immeuble de bureaux à Torrance pour environ 38 millions de dollars.
Herbalife (NYSE: HLF) hat die finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlicht, mit netto Verkaufszahlen von 1,3 Milliarden Dollar, was einem Rückgang von 2,5% im Vergleich zum Vorjahr aufgrund von Währungsbelastungen entspricht. Das Unternehmen erzielte jedoch ein Wachstum von 0,2% auf Basis konstanter Währungen. Zu den wichtigsten Punkten gehören:
- Bereinigtes EBITDA von 180,0 Millionen Dollar, das die Prognosen übertraf
- Bereinigter verwässerter Gewinn pro Aktie (EPS) von 0,54 Dollar
- Nettogewinn von 4,7 Millionen Dollar; bereinigter Nettogewinn von 54,8 Millionen Dollar
- Bruttogewinnmarge verbesserte sich auf 77,9%
- Rekrutierung neuer Vertriebspartner stieg um 12% im Vergleich zum Vorjahr
Das Unternehmen hob seine Prognose für das bereinigte EBITDA des Gesamtjahres 2024 an, während die Prognose für den Nettoumsatz gesenkt wurde. Herbalife hat zudem eine 1,6 Milliarden Dollar schwere Umschuldung abgeschlossen und sein Bürogebäude in Torrance für etwa 38 Millionen Dollar verkauft.
- Adjusted EBITDA of $180.0 million exceeded guidance
- Gross profit margin improved to 77.9% from 77.0% in Q2 2023
- New distributor recruitment increased 12% year-over-year
- Achieved 0.2% net sales growth on a constant currency basis
- Raised full-year 2024 adjusted EBITDA guidance
- Completed $1.6 billion debt refinancing
- Sold Torrance office building for approximately $38 million
- Restructuring Program expected to deliver annual savings of at least $80 million beginning in 2025
- Net sales decreased 2.5% year-over-year to $1.3 billion
- Reduced full-year 2024 net sales guidance
- Worldwide volume points decreased 6.0% year-over-year
- North America net sales declined 6.7% year-over-year
- China net sales decreased 7.2% year-over-year
Insights
Herbalife's Q2 2024 results present a mixed picture. While net sales declined
The standout metric is Adjusted EBITDA, which at
However, investors should note the significant gap between reported and adjusted figures. Net income of
The
Herbalife's revised full-year guidance, with lowered net sales expectations but raised Adjusted EBITDA projections, suggests management is prioritizing profitability over top-line growth in the current environment. This could be a prudent strategy, but investors should monitor whether this approach might impact long-term market share and growth potential.
Herbalife's Q2 results reveal interesting trends in its global markets. Latin America, EMEA and Asia Pacific regions showed growth on a constant currency basis, indicating resilience in these markets. However, North America and China experienced declines, which is concerning given these are typically strong markets for Herbalife.
The
However, the disconnect between distributor growth and volume points (down
The pricing adjustments made in Latin America, excluding Mexico, demonstrate Herbalife's willingness to adapt its strategy to local market conditions. This flexibility could help the company maintain competitiveness in price-sensitive markets, but it's important to monitor whether these adjustments will indeed stimulate the intended volume growth.
Overall, while Herbalife shows some positive trends in distributor recruitment and regional performance, the company faces challenges in translating these into consistent global growth. The success of its restructuring program and ability to leverage its expanded distributor base will be key factors to watch in the coming quarters.
“Our Q2 Adjusted EBITDA1 is the highest it’s been in seven quarters. We remain focused on driving shareholder value as the continued increase in new distributors builds the foundation for sales growth.” - Michael Johnson, Chairman and CEO
Highlights
Second Quarter 2024
-
Net sales of
, down$1.3 billion 2.5% vs. Q2 ’23 due to 270 basis points of FX headwinds-
Achieved year-over-year net sales growth on constant currency basis2, up
0.2% , driven by increases inLatin America , EMEA andAsia Pacific
-
Achieved year-over-year net sales growth on constant currency basis2, up
-
Net income of
; adjusted net income1 of$4.7 million $54.8 million -
Adjusted EBITDA1 of
exceeds guidance; adjusted EBITDA1 margin up 120 basis points year-over-year$180.0 million -
Diluted EPS of
; adjusted diluted EPS1 of$0.05 $0.54 -
Restructuring Program expenses, net of tax,
diluted EPS headwind; excluded from adjusted results$0.33 -
Loss on extinguishment of debt, net of tax,
diluted EPS headwind; excluded from adjusted results$0.07
-
Restructuring Program expenses, net of tax,
-
Net cash provided by operating activities of
; capital expenditures of approximately$102.5 million $36 million -
Credit Agreement EBITDA1
; total leverage ratio reduced to 3.5x at June 30$208.0 million
Recent Developments
-
Completed sale and sixteen-month leaseback of office building in
Torrance, California in July
Outlook
- Third quarter 2024 guidance provided
- Full-year 2024 guidance revised: net sales reduced, adjusted EBITDA1 raised, capital expenditures reaffirmed
_________________________
1 Non-GAAP measure. Refer to Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a detailed reconciliation of these measures to the most directly comparable
2 Growth/decline in net sales excluding the effects of foreign exchange is based on “net sales in local currency,” a non-GAAP financial measure. Refer to Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a discussion of why the Company believes adjusting for the effects of foreign exchange is useful.
Management Commentary
Herbalife reported second quarter 2024 net sales of
Second quarter gross profit margin improved to
Net income was
Net cash provided by operating activities was
The Company implemented further actions related to its Restructuring Program, which was initiated during the first quarter of 2024 and designed to bring leadership closer to its markets, streamline the employee structure and accelerate productivity. The Restructuring Program is expected to deliver annual savings of at least
As previously disclosed, the Company completed a
In July, the Company completed the sale and a sixteen-month leaseback transaction of its office building in
“We continue to make significant progress in our initiatives to enhance profitability,” said John DeSimone, Chief Financial Officer. “We remain focused on further expanding margins, creating shareholder value and reducing our total leverage ratio to 3.0x by the end of 2025.”
Over the past three months, approximately 83,300 attendees from around the world convened at Extravaganza training events in
For the second quarter of 2024, the number of new distributors joining Herbalife worldwide increased
“This is an exciting time at Herbalife and while we have work to do, there are many good things happening,” said Michael Johnson. “Our Adjusted EBITDA1 margins are up, we’ve reduced our total leverage ratio to 3.5x, distributor recruiting is up and distributors are engaged in building their businesses.”
Second Quarter and Year to Date 2024 Key Metrics
Regional Net Sales and Foreign Exchange (“FX”) Impact |
|||||||||
|
Reported Net Sales |
|
YoY Growth (Decline) |
||||||
$ million |
Q2 ‘24 |
Q2 ‘23 |
|
including FX |
excluding FX2 |
||||
|
$ |
283.2 |
$ |
303.6 |
|
(6.7 |
)% |
(6.7 |
)% |
|
|
211.7 |
|
207.0 |
|
2.3 |
% |
4.7 |
% |
EMEA |
|
287.8 |
|
289.6 |
|
(0.6 |
)% |
3.5 |
% |
|
|
416.7 |
|
425.8 |
|
(2.1 |
)% |
1.6 |
% |
|
|
81.7 |
|
88.0 |
|
(7.2 |
)% |
(4.0 |
)% |
Worldwide |
$ |
1,281.1 |
$ |
1,314.0 |
|
(2.5 |
)% |
0.2 |
% |
|
Reported Net Sales |
|
YoY Growth (Decline) |
||||||
$ million |
YTD ‘24 |
YTD ‘23 |
|
including FX |
excluding FX2 |
||||
|
$ |
549.0 |
$ |
600.8 |
|
(8.6 |
)% |
(8.6 |
)% |
|
|
425.9 |
|
412.5 |
|
3.2 |
% |
3.3 |
% |
EMEA |
|
565.7 |
|
557.7 |
|
1.4 |
% |
4.9 |
% |
|
|
847.9 |
|
839.4 |
|
1.0 |
% |
4.2 |
% |
|
|
156.9 |
|
155.7 |
|
0.8 |
% |
5.0 |
% |
Worldwide |
$ |
2,545.4 |
$ |
2,566.1 |
|
(0.8 |
)% |
1.3 |
% |
Regional Volume Point Metrics |
|||||||||
|
Volume Points |
||||||||
in millions |
Q2 ‘24 |
Q2 ‘23 |
YoY % Chg. |
|
YTD ‘24 |
YTD ‘23 |
YoY % Chg. |
||
|
272.5 |
313.4 |
(13.1 |
)% |
|
536.7 |
627.9 |
(14.5 |
)% |
|
253.2 |
258.5 |
(2.1 |
)% |
|
508.5 |
529.9 |
(4.0 |
)% |
EMEA |
299.2 |
331.2 |
(9.7 |
)% |
|
597.9 |
645.5 |
(7.4 |
)% |
|
520.2 |
530.5 |
(1.9 |
)% |
|
1,048.6 |
1,035.7 |
1.2 |
% |
|
61.5 |
62.6 |
(1.8 |
)% |
|
116.3 |
111.2 |
4.6 |
% |
Worldwide(b) |
1,406.6 |
1,496.2 |
(6.0 |
)% |
|
2,808.0 |
2,950.2 |
(4.8 |
)% |
Note: During Q2 ‘24, most markets within the
(a) |
Excluding the Volume Point adjustments noted above, the year-over-year percentage change for Q2 ’24 and YTD ‘24 would have been a decrease of |
|
(b) |
Excluding the Volume Point adjustments noted above, the year-over-year percentage change for Q2 ’24 and YTD ‘24 would have been a decrease of |
Outlook
Third Quarter 2024 Guidance |
||
$ million |
Q3 ‘24 Guidance |
Q3 ‘23 Results |
Net Sales |
(4.5)% to |
1,281.3 |
Adjusted EBITDA1 |
125 – 155 |
163.3 |
Capital Expenditures |
35 – 45 |
31.1 |
Full-Year 2024 Guidance – Revised
$ million |
FY ‘24 Guidance REVISED |
|
FY ‘24 Guidance (as of May 1 ’24) |
FY ‘23 Results |
Net Sales |
(3.5)% to + |
Reduced |
|
5,062.4 |
Adjusted EBITDA1 |
560 – 600 |
Raised |
550 – 590 |
570.6 |
Capital Expenditures |
120 – 150 |
Reaffirmed |
120 – 150 |
135.0 |
Earnings Webcast and Conference Call
Herbalife’s senior management team will host a live audio webcast and conference call to discuss its second quarter 2024 financial results on Wednesday, July 31, 2024, at 5:30 p.m. ET (2:30 p.m. PT).
The live audio webcast will be available at the following link: https://edge.media-server.com/mmc/p/ebzt6ttw.
Participants joining via the conference call may obtain the dial-in information and personal PIN to access the call by registering at the following link: https://register.vevent.com/register/BI912a2bd326f64fcfb80efc4f2f34d208.
Senior management also plans to reference slides during the webcast and call, which will be available under the Investor Relations section of Herbalife’s website at https://ir.herbalife.com, where financial and other information is posted from time to time. The live webcast will also be available at the same website, along with a replay of the webcast following the completion of the event and for 12 months thereafter.
About Herbalife Ltd.
Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life.
For more information, visit https://ir.herbalife.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management, including for future operations, capital expenditures, or share repurchases; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; any statements of belief or expectation; and any statements of assumptions underlying any of the foregoing or other future events. Forward-looking statements may include, among others, the words “may,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect,” “anticipate” or any other similar words.
Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results or outcomes could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, many of which are beyond our control. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in or implied by our forward-looking statements include the following:
- the potential impacts of current global economic conditions, including inflation, on us; our Members, customers, and supply chain; and the world economy;
- our ability to attract and retain Members;
- our relationship with, and our ability to influence the actions of, our Members;
-
our noncompliance with, or improper action by our employees or Members in violation of, applicable
U.S. and foreign laws, rules, and regulations; - adverse publicity associated with our Company or the direct-selling industry, including our ability to comfort the marketplace and regulators regarding our compliance with applicable laws;
- changing consumer preferences and demands and evolving industry standards, including with respect to climate change, sustainability, and other environmental, social, and governance, or ESG, matters;
- the competitive nature of our business and industry;
- legal and regulatory matters, including regulatory actions concerning, or legal challenges to, our products or network marketing program and product liability claims;
- the Consent Order entered into with the Federal Trade Commission, or FTC, the effects thereof and any failure to comply therewith;
-
risks associated with operating internationally and in
China ; - our ability to execute our growth and other strategic initiatives, including implementation of our restructuring initiatives, and increased penetration of our existing markets;
-
any material disruption to our business caused by natural disasters, other catastrophic events, acts of war or terrorism, including the war in
Ukraine , cybersecurity incidents, pandemics, and/or other acts by third parties; - our ability to adequately source ingredients, packaging materials, and other raw materials and manufacture and distribute our products;
- our reliance on our information technology infrastructure;
- noncompliance by us or our Members with any privacy laws, rules, or regulations or any security breach involving the misappropriation, loss, or other unauthorized use or disclosure of confidential information;
- contractual limitations on our ability to expand or change our direct-selling business model;
- the sufficiency of our trademarks and other intellectual property;
- product concentration;
- our reliance upon, or the loss or departure of any member of, our senior management team;
- restrictions imposed by covenants in the agreements governing our indebtedness;
- risks related to our convertible notes;
- changes in, and uncertainties relating to, the application of transfer pricing, income tax, customs duties, value added taxes, and other tax laws, treaties, and regulations, or their interpretation;
-
our incorporation under the laws of the
Cayman Islands ; and - share price volatility related to, among other things, speculative trading and certain traders shorting our common shares.
Additional factors and uncertainties that could cause actual results or outcomes to differ materially from our forward-looking statements are set forth in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024, filed with the Securities and Exchange Commission on July 31, 2024, including under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our Condensed Consolidated Financial Statements and the related Notes included therein, and Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 14, 2024, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our Consolidated Financial Statements and the related Notes included therein. In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future.
Forward-looking statements made in this release speak only as of the date hereof. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Results of Operations
Herbalife Ltd. and Subsidiaries | |||||||||||||||
Condensed Consolidated Statements of Income | |||||||||||||||
(in millions, except per share amounts) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2024 |
2023 |
2024 |
2023 |
||||||||||||
(unaudited) |
|||||||||||||||
$ |
283.2 |
$ |
303.6 |
|
$ |
549.0 |
$ |
600.8 |
|
||||||
|
211.7 |
|
207.0 |
|
|
425.9 |
|
412.5 |
|
||||||
EMEA |
|
287.8 |
|
289.6 |
|
|
565.7 |
|
557.7 |
|
|||||
|
416.7 |
|
425.8 |
|
|
847.9 |
|
839.4 |
|
||||||
|
81.7 |
|
88.0 |
|
|
156.9 |
|
155.7 |
|
||||||
Worldwide Net sales |
|
1,281.1 |
|
1,314.0 |
|
|
2,545.4 |
|
2,566.1 |
|
|||||
Cost of sales |
|
283.1 |
|
301.6 |
|
|
568.1 |
|
600.2 |
|
|||||
Gross profit |
|
998.0 |
|
1,012.4 |
|
|
1,977.3 |
|
1,965.9 |
|
|||||
Royalty overrides |
|
415.3 |
|
429.7 |
|
|
830.5 |
|
845.7 |
|
|||||
Selling, general, and administrative expenses |
|
502.3 |
|
460.5 |
|
|
994.5 |
|
936.4 |
|
|||||
Other operating income (1) |
|
- |
|
(1.2 |
) |
|
- |
|
(10.1 |
) |
|||||
Operating income |
|
80.4 |
|
123.4 |
|
|
152.3 |
|
193.9 |
|
|||||
Interest expense, net |
|
57.7 |
|
38.4 |
|
|
95.6 |
|
77.8 |
|
|||||
Other expense, net (2) |
|
10.5 |
|
- |
|
|
10.5 |
|
- |
|
|||||
Income before income taxes |
|
12.2 |
|
85.0 |
|
|
46.2 |
|
116.1 |
|
|||||
Income taxes |
|
7.5 |
|
25.1 |
|
|
17.2 |
|
26.9 |
|
|||||
Net income | $ |
4.7 |
$ |
59.9 |
|
$ |
29.0 |
$ |
89.2 |
|
|||||
Weighted-average shares outstanding: | |||||||||||||||
Basic |
|
100.6 |
|
99.1 |
|
|
100.1 |
|
98.8 |
|
|||||
Diluted |
|
101.7 |
|
99.5 |
|
|
101.2 |
|
99.8 |
|
|||||
Earnings per share: | |||||||||||||||
Basic | $ |
0.05 |
$ |
0.60 |
|
$ |
0.29 |
$ |
0.90 |
|
|||||
Diluted | $ |
0.05 |
$ |
0.60 |
|
$ |
0.29 |
$ |
0.89 |
|
|||||
(1) Other operating income for the three and six months ended June 30, 2023 relates to certain |
|||||||||||||||
(2) Other expense, net for the three and six months ended June 30, 2024 relates to loss on extinguishment of 2018 Credit Facility, as well as partial redemption and private repurchase of 2025 Notes |
Herbalife Ltd. and Subsidiaries | |||||||||
Condensed Consolidated Balance Sheets | |||||||||
(in millions) | |||||||||
June 30, | December 31, | ||||||||
2024 |
2023 |
||||||||
(unaudited) | |||||||||
ASSETS | |||||||||
Current Assets: | |||||||||
Cash and cash equivalents | $ |
374.0 |
|
$ |
575.2 |
|
|||
Receivables, net |
|
82.8 |
|
|
81.2 |
|
|||
Inventories |
|
480.7 |
|
|
505.2 |
|
|||
Prepaid expenses and other current assets |
|
276.3 |
|
|
237.7 |
|
|||
Total Current Assets |
|
1,213.8 |
|
|
1,399.3 |
|
|||
Property, plant and equipment, net |
|
468.2 |
|
|
506.5 |
|
|||
Operating lease right-of-use assets |
|
188.3 |
|
|
185.8 |
|
|||
Marketing-related intangibles and other intangible assets, net |
|
313.1 |
|
|
314.0 |
|
|||
Goodwill |
|
91.5 |
|
|
95.4 |
|
|||
Other assets |
|
327.3 |
|
|
308.4 |
|
|||
Total Assets | $ |
2,602.2 |
|
$ |
2,809.4 |
|
|||
LIABILITIES AND SHAREHOLDERS' DEFICIT | |||||||||
Current Liabilities: | |||||||||
Accounts payable | $ |
81.3 |
|
$ |
84.0 |
|
|||
Royalty overrides |
|
316.5 |
|
|
343.4 |
|
|||
Current portion of long-term debt |
|
21.7 |
|
|
309.5 |
|
|||
Other current liabilities |
|
556.7 |
|
|
540.7 |
|
|||
Total Current Liabilities |
|
976.2 |
|
|
1,277.6 |
|
|||
Non-current liabilities: | |||||||||
Long-term debt, net of current portion |
|
2,321.0 |
|
|
2,252.9 |
|
|||
Non-current operating lease liabilities |
|
173.3 |
|
|
167.6 |
|
|||
Other non-current liabilities |
|
168.9 |
|
|
171.6 |
|
|||
Total Liabilities |
|
3,639.4 |
|
|
3,869.7 |
|
|||
Commitments and Contingencies | |||||||||
Shareholders' deficit: | |||||||||
Common shares |
|
0.1 |
|
|
0.1 |
|
|||
Paid-in capital in excess of par value |
|
253.4 |
|
|
233.9 |
|
|||
Accumulated other comprehensive loss |
|
(257.4 |
) |
|
(232.0 |
) |
|||
Accumulated deficit |
|
(1,033.3 |
) |
|
(1,062.3 |
) |
|||
Total Shareholders' Deficit |
|
(1,037.2 |
) |
|
(1,060.3 |
) |
|||
Total Liabilities and Shareholders' Deficit | $ |
2,602.2 |
|
$ |
2,809.4 |
|
|||
Herbalife Ltd. and Subsidiaries | |||||||||
Condensed Consolidated Statements of Cash Flows | |||||||||
(in millions) | |||||||||
Six Months Ended June 30, | |||||||||
2024 |
2023 |
||||||||
(unaudited) | |||||||||
Cash flows from operating activities: | |||||||||
Net income | $ |
29.0 |
|
$ |
89.2 |
|
|||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
Depreciation and amortization |
|
61.8 |
|
|
56.7 |
|
|||
Share-based compensation expenses |
|
23.7 |
|
|
22.0 |
|
|||
Non-cash interest expense |
|
5.6 |
|
|
3.6 |
|
|||
Deferred income taxes |
|
(27.5 |
) |
|
(8.4 |
) |
|||
Inventory write-downs |
|
11.4 |
|
|
16.9 |
|
|||
Foreign exchange transaction loss (gain) |
|
4.5 |
|
|
1.0 |
|
|||
Loss on extinguishment of debt |
|
10.5 |
|
|
- |
|
|||
Other |
|
2.8 |
|
|
3.4 |
|
|||
Changes in operating assets and liabilities: | |||||||||
Receivables |
|
(5.1 |
) |
|
(16.6 |
) |
|||
Inventories |
|
(6.6 |
) |
|
50.7 |
|
|||
Prepaid expenses and other current assets |
|
(6.4 |
) |
|
(17.5 |
) |
|||
Accounts payable |
|
(3.5 |
) |
|
(0.8 |
) |
|||
Royalty overrides |
|
(19.2 |
) |
|
(21.3 |
) |
|||
Other current liabilities |
|
41.2 |
|
|
15.3 |
|
|||
Other |
|
(5.9 |
) |
|
(12.4 |
) |
|||
Net cash provided by operating activities |
|
116.3 |
|
|
181.8 |
|
|||
Cash flows from investing activities: | |||||||||
Purchases of property, plant and equipment |
|
(69.2 |
) |
|
(68.6 |
) |
|||
Other |
|
0.2 |
|
|
0.1 |
|
|||
Net cash used in investing activities |
|
(69.0 |
) |
|
(68.5 |
) |
|||
Cash flows from financing activities: | |||||||||
Borrowings from senior secured credit facility and other debt |
|
961.7 |
|
|
71.0 |
|
|||
Principal payments on senior secured credit facility and other debt |
|
(1,413.8 |
) |
|
(146.7 |
) |
|||
Repayment of convertible senior notes |
|
(197.0 |
) |
|
- |
|
|||
Proceeeds from senior secured notes, net of discount |
|
778.4 |
|
|
- |
|
|||
Repayment of senior notes |
|
(344.3 |
) |
|
- |
|
|||
Debt issuance costs |
|
(20.9 |
) |
|
(1.8 |
) |
|||
Share repurchases |
|
(5.7 |
) |
|
(9.4 |
) |
|||
Other |
|
1.4 |
|
|
1.6 |
|
|||
Net cash used in financing activities |
|
(240.2 |
) |
|
(85.3 |
) |
|||
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
|
(13.3 |
) |
|
3.0 |
|
|||
Net change in cash, cash equivalents, and restricted cash |
|
(206.2 |
) |
|
31.0 |
|
|||
Cash, cash equivalents, and restricted cash, beginning of period |
|
595.5 |
|
|
516.3 |
|
|||
Cash, cash equivalents, and restricted cash, end of period | $ |
389.3 |
|
$ |
547.3 |
|
|||
Supplemental Information
SCHEDULE A: RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (unaudited)
Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA and Credit Agreement EBITDA
In addition to its reported results calculated in accordance with
Management believes that such non-GAAP performance measures, when read in conjunction with the Company’s reported results, calculated in accordance with
The Company’s definitions and calculations as set forth in the tables below of adjusted net income, adjusted diluted EPS, adjusted EBITDA and credit agreement EBITDA may not be comparable to similarly titled measures used by other companies because other companies may not calculate them in the same manner as the Company does and should not be viewed in isolation from, nor as alternatives to, net income or diluted EPS calculated in accordance with
The Company does not provide a reconciliation of forward-looking adjusted EBITDA guidance to net income, the comparable
Currency Fluctuation
Our international operations have provided and will continue to provide a significant portion of our total net sales. As a result, total net sales will continue to be affected by fluctuations in the
The following is a reconciliation of net income to adjusted net income:
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
$ million | 2024 |
2023 |
2024 |
2023 |
|||||||||||||
Net income | $ |
4.7 |
|
$ |
59.9 |
|
$ |
29.0 |
|
$ |
89.2 |
|
|||||
Expenses related to Restructuring Program (1) (2) |
|
48.8 |
|
|
- |
|
|
65.5 |
|
|
- |
|
|||||
Expenses related to Transformation Program (1) (2) |
|
3.5 |
|
|
10.1 |
|
|
9.4 |
|
|
37.4 |
|
|||||
Digital technology program costs (1) (2) |
|
6.0 |
|
|
7.0 |
|
|
17.0 |
|
|
10.5 |
|
|||||
Loss on extinguishment of debt (1) (2) |
|
10.5 |
|
|
- |
|
|
10.5 |
|
|
- |
|
|||||
Income tax adjustments for above items (1) (2) |
|
(18.7 |
) |
|
(3.0 |
) |
|
(27.3 |
) |
|
(9.2 |
) |
|||||
Adjusted net income | $ |
54.8 |
|
$ |
74.0 |
|
$ |
104.1 |
|
$ |
127.9 |
|
|||||
The following is a reconciliation of diluted earnings per share to adjusted diluted earnings per share:
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
$ per share | 2024 |
2023 |
2024 |
2023 |
|||||||||||||
Diluted earnings per share | $ |
0.05 |
|
$ |
0.60 |
|
$ |
0.29 |
|
$ |
0.89 |
|
|||||
Expenses related to Restructuring Program (1) (2) |
|
0.48 |
|
|
- |
|
|
0.65 |
|
|
- |
|
|||||
Expenses related to Transformation Program (1) (2) |
|
0.03 |
|
|
0.10 |
|
|
0.09 |
|
|
0.37 |
|
|||||
Digital technology program costs (1) (2) |
|
0.06 |
|
|
0.07 |
|
|
0.17 |
|
|
0.11 |
|
|||||
Loss on extinguishment of debt (1) (2) |
|
0.10 |
|
|
- |
|
|
0.10 |
|
|
- |
|
|||||
Income tax adjustments for above items (1) (2) |
|
(0.18 |
) |
|
(0.03 |
) |
|
(0.27 |
) |
|
(0.09 |
) |
|||||
Adjusted diluted earnings per share | $ |
0.54 |
|
$ |
0.74 |
|
$ |
1.03 |
|
$ |
1.28 |
|
|||||
The following is a reconciliation of net income to EBITDA, adjusted EBITDA and Credit Agreement EBITDA and Credit Agreement total leverage ratio:
Three Months Ended | TTM | ||||||||||||||||||||||||
$ million | Jun 30 '23 | Sep 30 '23 | Dec 31 '23 | Mar 31 '24 | Jun 30 '24 | Jun 30 '24 | |||||||||||||||||||
Net sales | $ |
1,314.0 |
|
$ |
1,281.3 |
|
$ |
1,215.0 |
|
$ |
1,264.3 |
|
$ |
1,281.1 |
|
$ |
5,041.7 |
|
|||||||
Net income | $ |
59.9 |
|
$ |
42.8 |
|
$ |
10.2 |
|
$ |
24.3 |
|
$ |
4.7 |
|
$ |
82.0 |
|
|||||||
Interest expense, net |
|
38.4 |
|
|
38.5 |
|
|
38.1 |
|
|
37.9 |
|
|
57.7 |
|
|
172.2 |
|
|||||||
Income taxes |
|
25.1 |
|
|
26.4 |
|
|
7.5 |
|
|
9.7 |
|
|
7.5 |
|
|
51.1 |
|
|||||||
Depreciation and amortization |
|
29.1 |
|
|
28.4 |
|
|
28.2 |
|
|
29.2 |
|
|
32.6 |
|
|
118.4 |
|
|||||||
EBITDA |
|
152.5 |
|
|
136.1 |
|
|
84.0 |
|
|
101.1 |
|
|
102.5 |
|
|
423.7 |
|
|||||||
Amortization of SaaS implementation costs |
|
- |
|
|
2.9 |
|
|
3.1 |
|
|
3.6 |
|
|
8.7 |
|
|
18.3 |
|
|||||||
Expenses related to Restructuring Program |
|
- |
|
|
- |
|
|
- |
|
|
16.7 |
|
|
48.8 |
|
|
65.5 |
|
|||||||
Expenses related to Transformation Program |
|
10.1 |
|
|
4.6 |
|
|
12.2 |
|
|
5.9 |
|
|
3.5 |
|
|
26.2 |
|
|||||||
Digital technology program costs |
|
7.0 |
|
|
12.1 |
|
|
9.5 |
|
|
11.0 |
|
|
6.0 |
|
|
38.6 |
|
|||||||
(Gain) loss on extinguishment of debt |
|
- |
|
|
(1.0 |
) |
|
- |
|
|
- |
|
|
10.5 |
|
|
9.5 |
|
|||||||
|
- |
|
|
8.6 |
|
|
- |
|
|
- |
|
|
- |
|
|
8.6 |
|
||||||||
Adjusted EBITDA | $ |
169.6 |
|
$ |
163.3 |
|
$ |
108.8 |
|
$ |
138.3 |
|
$ |
180.0 |
|
$ |
590.4 |
|
|||||||
Adjusted EBITDA margin |
|
12.9 |
% |
|
12.7 |
% |
|
9.0 |
% |
|
10.9 |
% |
|
14.1 |
% |
|
11.7 |
% |
|||||||
Interest income |
|
2.7 |
|
|
3.2 |
|
|
3.2 |
|
|
3.7 |
|
|
2.8 |
|
|
12.9 |
|
|||||||
Inventory write-downs |
|
5.4 |
|
|
5.0 |
|
|
6.6 |
|
|
4.7 |
|
|
6.7 |
|
|
23.0 |
|
|||||||
Share-based compensation expenses |
|
11.2 |
|
|
13.7 |
|
|
12.3 |
|
|
11.9 |
|
|
11.8 |
|
|
49.7 |
|
|||||||
Other expenses (3) |
|
(1.2 |
) |
|
(3.8 |
) |
|
11.8 |
|
|
0.9 |
|
|
6.7 |
|
|
15.6 |
|
|||||||
Credit Agreement EBITDA | $ |
187.7 |
|
$ |
181.4 |
|
$ |
142.7 |
|
$ |
159.5 |
|
$ |
208.0 |
|
$ |
691.6 |
|
|||||||
Credit Agreement Total Debt (4) | $ |
2,422.5 |
|
||||||||||||||||||||||
Credit Agreement Total Leverage Ratio | 3.5x | ||||||||||||||||||||||||
The following is a reconciliation of net income to EBITDA, adjusted EBITDA and Credit Agreement EBITDA and Credit Agreement total leverage ratio:
Six Months Ended June 30, | Year Ended Dec 31, | ||||||||||||
$ million | 2024 |
2023 |
2023 |
||||||||||
Net sales | $ |
2,545.4 |
|
$ |
2,566.1 |
|
$ |
5,062.4 |
|
||||
Net income | $ |
29.0 |
|
$ |
89.2 |
|
$ |
142.2 |
|
||||
Interest expense, net |
|
95.6 |
|
|
77.8 |
|
|
154.4 |
|
||||
Income taxes |
|
17.2 |
|
|
26.9 |
|
|
60.8 |
|
||||
Depreciation and amortization |
|
61.8 |
|
|
56.7 |
|
|
113.3 |
|
||||
EBITDA |
|
203.6 |
|
|
250.6 |
|
|
470.7 |
|
||||
Amortization of SaaS implementation costs |
|
12.3 |
|
|
- |
|
|
6.0 |
|
||||
Expenses related to Restructuring Program |
|
65.5 |
|
|
- |
|
|
- |
|
||||
Expenses related to Transformation Program |
|
9.4 |
|
|
37.4 |
|
|
54.2 |
|
||||
Digital technology program costs |
|
17.0 |
|
|
10.5 |
|
|
32.1 |
|
||||
(Gain) loss on extinguishment of debt |
|
10.5 |
|
|
- |
|
|
(1.0 |
) |
||||
|
- |
|
|
- |
|
|
8.6 |
|
|||||
Adjusted EBITDA | $ |
318.3 |
|
$ |
298.5 |
|
$ |
570.6 |
|
||||
Adjusted EBITDA margin |
|
12.5 |
% |
|
11.6 |
% |
|
11.3 |
% |
||||
Interest income |
|
6.5 |
|
|
5.1 |
|
|
11.5 |
|
||||
Inventory write-downs |
|
11.4 |
|
|
16.9 |
|
|
28.5 |
|
||||
Share-based compensation expenses |
|
23.7 |
|
|
22.0 |
|
|
48.0 |
|
||||
Other expenses (3) |
|
7.6 |
|
|
3.5 |
|
|
11.5 |
|
||||
Credit Agreement EBITDA | $ |
367.5 |
|
$ |
346.0 |
|
$ |
670.1 |
|
||||
Credit Agreement Total Debt (4) | $ |
2,581.1 |
|
||||||||||
Credit Agreement Total Leverage Ratio | 3.9x | ||||||||||||
(1) Based on interim income tax reporting rules, these expenses are not considered discrete items. The tax effect of the adjustments between our |
|||||||||||||||
(2) Excludes tax (benefit)/expense as follows: | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
$ million | 2024 |
2023 |
2024 |
2023 |
|||||||||||
Expenses related to Restructuring Program | $ |
(15.7 |
) |
$ |
- |
|
$ |
(20.2 |
) |
$ |
- |
|
|||
Expenses related to Transformation Program |
|
(0.5 |
) |
|
(2.5 |
) |
|
(2.5 |
) |
|
(8.5 |
) |
|||
Digital technology program costs |
|
0.1 |
|
|
(0.5 |
) |
|
(2.0 |
) |
|
(0.7 |
) |
|||
Loss on extinguishment of debt |
|
(2.6 |
) |
|
- |
|
|
(2.6 |
) |
|
- |
|
|||
Total income tax adjustments | $ |
(18.7 |
) |
$ |
(3.0 |
) |
$ |
(27.3 |
) |
$ |
(9.2 |
) |
|||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
$ per share | 2024 |
2023 |
2024 |
2023 |
|||||||||||
Expenses related to Restructuring Program | $ |
(0.15 |
) |
$ |
- |
|
$ |
(0.20 |
) |
$ |
- |
|
|||
Expenses related to Transformation Program |
|
- |
|
|
(0.02 |
) |
|
(0.02 |
) |
|
(0.09 |
) |
|||
Digital technology program costs |
|
- |
|
|
(0.01 |
) |
|
(0.02 |
) |
|
(0.01 |
) |
|||
Loss on extinguishment of debt |
|
(0.03 |
) |
|
- |
|
|
(0.03 |
) |
|
- |
|
|||
Total income tax adjustments (5) | $ |
(0.18 |
) |
$ |
(0.03 |
) |
$ |
(0.27 |
) |
$ |
(0.09 |
) |
|||
(3) Other expenses include certain non-cash items such as bad debt expense, unrealized foreign currency gains and losses, and other gains and losses | |||||||||||||||
(4) Represents the outstanding principal amount of total debt as of the respective period end | |||||||||||||||
(5) Amounts may not total due to rounding |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730118998/en/
Media Contact:
Thien Ho
Vice President, Global Corporate Communications
thienh@herbalife.com
Investor Contact:
Erin Banyas
Vice President, Head of Investor Relations
erinba@herbalife.com
Source: Herbalife Ltd.
FAQ
What were Herbalife's Q2 2024 net sales?
How did Herbalife's adjusted EBITDA perform in Q2 2024?
What was Herbalife's (HLF) adjusted diluted EPS for Q2 2024?
How did Herbalife's new distributor recruitment perform in Q2 2024?